퇴행성 추간판 질환 시장 : 시장 인사이트, 역학 및 시장 예측(2032년)

Degenerative Disc Disease- Market Insight, Epidemiology And Market Forecast - 2032

US $ 7,500 ￦ 10,669,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,250 ￦ 16,004,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,000 ￦ 21,339,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 22,500 ￦ 32,008,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

추간판 퇴행성 질환(DDD) 시장은 예측 기간(2023-2032년) 동안 안정적인 성장세를 보일 것으로 예상됩니다. 주요 7개국에서 추간판 퇴행성 질환 시장 규모는 더 나은 진단과 새로운 치료법 출시로 인해 확대될 것으로 예상됩니다.

주요 7개국에서 진단받은 추간판 퇴행성 질환 유병자 중 약 50%가 미국에서 온 환자로 추정됩니다. 2022년에는 EU 4개국과 영국에서 약 840만 명의 DDD 환자가 진단을 받았습니다. 주요 7개국에서 시장은 주로 비스테로이드성 항염증제(NSAIDs), 오피오이드, 기타로 구성되며, 2022년 약 35억 7,200만 달러 시장을 창출했습니다.

퇴행성 추간판 질환(DDD)은 척추의 유연성과 충격 흡수를 제공하는 척추뼈와 척추뼈 사이의 쿠션인 추간판이 점차적으로 퇴화되는 척추 질환입니다. 일반적인 증상으로는 지속적인 통증, 뻣뻣함, 진행되면 약화 및 마비 등이 있으며, DDD의 위험 요인으로는 노화, 유전적 소인, 반복적인 운동이나 격렬한 운동을 수반하는 특정 직업, 비만 등이 있습니다. 이 질환은 척추의 자연적인 마모와 손상, 추간판 액체의 손실, 부상이나 스트레스로 인한 작은 균열이나 균열, 염증 등으로 인해 발생합니다.

추간판 퇴행성 질환(DDD)의 진단에는 병력, 신체 검사 및 영상 검사를 결합한 종합적인 접근이 필요합니다. 의료진은 철저한 병력 청취를 통해 환자의 증상, 기간, 통증에 영향을 미치는 모든 요인에 대한 정보를 수집합니다. 신체 검사는 환자의 운동 범위와 신경학적 기능을 평가하고, 엑스레이, MRI, CT 스캔과 같은 영상 검사는 척추의 상세한 이미지를 제공하여 추간판 변성, 탈장 및 잠재적인 신경 압박을 강조합니다. 경우에 따라 보다 정밀한 평가를 위해 추간판에 조영제를 주입하는 추간판 조영술을 시행할 수도 있습니다. 뼈 스캔, 근전도 검사, 신경전도 검사는 드물지만 특정 상황에서 고려될 수 있습니다. 진단은 최종적으로 임상 소견과 영상진단 결과의 상관관계에 따라 이루어집니다.

주요 7개국에서 추간판 퇴행성 질환 시장 규모는 2022년 35억 7,200만 달러에 달했습니다. 이 시장은 예측 기간 동안 확대될 것으로 예상됩니다. 그 중 미국은 2022년 시장을 독점하며 62%에 가까운 가장 큰 점유율을 차지했습니다.

본 보고서는 주요 7개국의 추간판 변성 질환 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2032년까지 시장 규모 예측, 미충족 의료 수요 등을 조사하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 보고서 서론

제3장 퇴행성 추간판 질환(DDD) 시장 개요

제4장 DDD 역학과 시장 조사 방법

제5장 추간판 변성 질환(DDD) 주요 요약

제6장 주요 이벤트

제7장 추간판 변성 질환(DDD) 배경과 개요

• 서론
• DDD의 유형
• 임상 분류
• DDD의 단계
• 병인
• 위험 요인
• 임상 증상과 증상
• 병태생리학
• 진단
• 치료와 관리

제8장 역학과 환자수

• 주요 조사 결과
• 전제조건과 근거
• 주요 7개국에서 진단된 DDD 이환 증례 합계
• 미국
• EU 4개국과 영국
• 일본

제9장 환자 동향

제10장 신흥 약제

제11장 DDD : 시장 분석

• 주요 조사 결과
• 주요 시장 예측의 전제조건
• 시장 전망
• 콘조인트 분석
• 주요 7개국 DDD 전체 시장 규모
• 주요 7개국 DDD 시장 규모, 치료법별
• 미국의 DDD 시장 규모
• EU 4개국 및 영국의 DDD 시장 규모
• 일본의 DDD 시장 규모

제12장 주요 업계 리더의 견해

제13장 SWOT 분석

제14장 미충족 요구

제15장 시장 접근과 상환

• 미국
• EU 4개국과 영국
• 일본

제16장 부록

제17장 DelveInsight의 서비스 내용

제18장 면책사항

LSH

영문 목차

영문목차

Key Highlights:

• The Degenerative Disc Disease (DDD) market is projected to witness consistent growth throughout the forecast period (2023-2032). The market size of DDD in the 7MM is expected to increase, driven by better diagnosis and the launch of emerging therapies.
• DelveInsight's analyst projects that among the total diagnosed prevalent cases of degenerative disc disease in 7MM approximately 50% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 8.4 million diagnosed prevalent cases of DDD.
• In the 7MM, the market mainly consisted of NSAID, opioids and others, which generated nearly USD 3,572 million in 2022.
• The total market size of the DDD treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Rexlemestrocel-L (MPC-06-ID), IDCT (Rebonuputemcel), and others.

DelveInsight's "Degenerative Disc Disease (DDD)- Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Degenerative Disc Disease (DDD), historical and forecasted epidemiology and the DDD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The DDD market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Degenerative Disc Disease (DDD) market size from 2019 to 2032. The report also covers current DDD treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Disease Understanding and Treatment Algorithm

Degenerative Disc Disease (DDD) Overview

Degenerative Disc Disease (DDD) is a spinal condition characterized by the gradual deterioration of intervertebral discs, the cushions between vertebrae that provide spinal flexibility and shock absorption. Common symptoms include persistent pain, stiffness, and, in advanced cases, weakness or numbness. Risk factors for DDD include aging, genetic predisposition, certain occupations involving repetitive or strenuous activities, and obesity. The condition arises from the natural wear and tear on the spine, loss of disc fluid, small tears or cracks due to injuries or stress, and inflammation.

Degenerative Disc Disease (DDD) Diagnosis

Diagnosing Degenerative Disc Disease (DDD) involves a comprehensive approach combining medical history, physical examination, and imaging studies. Healthcare providers gather information about the patient's symptoms, their duration, and any factors influencing pain during a thorough medical history. Physical examinations assess the patient's range of motion and neurological function. Imaging studies, such as X-rays, MRIs, and CT scans, offer detailed views of the spine, highlighting disc degeneration, herniation, and potential nerve compression. In some cases, discography may be performed, involving the injection of contrast dye into discs for a more precise assessment. While bone scans and electromyography or nerve conduction studies are rarely used, they may be considered in specific situations. The diagnosis is ultimately based on the correlation between clinical findings and imaging results

Degenerative Disc Disease (DDD) Treatment

Currently, there is no pharmaceutical treatment for DDD. Available treatments can control symptoms and often allow one to have a relatively high quality of life.

The treatment and management of Degenerative Disc Disease (DDD) involve a multifaceted approach tailored to alleviate symptoms and enhance overall well-being. Conservative measures, such as over-the-counter or prescription medications, aim to mitigate pain and inflammation. Physical therapy, incorporating targeted exercises and manual techniques, plays a crucial role in strengthening supporting muscles and improving spinal flexibility. Lifestyle modifications, including activity adjustments and weight management, are essential to reduce strain on the spine. In some cases, injections like epidural steroids may be administered to alleviate localized pain. Surgery is considered when conservative measures fail to provide relief or when there's significant nerve compression, aiming to alleviate symptoms and improve the quality of life for those with DDD.

Several emerging treatments for DDD are currently in the process of development. These encompass TGFB1 antagonists, cell replacements, parathyroid hormone replacements, and other options.

Degenerative Disc Disease (DDD) Epidemiology

As the market is derived using the patient-based model, the DDD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of CLBP, Total Diagnosed Prevalent Cases of DDD, Gender-specific Diagnosed Prevalent cases of DDD, Age-specific Diagnosed Prevalent cases of DDD, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. As per DelveInsight's estimations, the total diagnosed prevalent cases of DDD in the 7MM was approximately 25.5 million cases in 2022 and are projected to increase during the forecast period.

• The total diagnosed prevalent cases of CLBP in the 7MM were 63.7 million in 2022. These cases is expected to grow at a significant CAGR during the study period (2019-2032).
• Of 32 million diagnosed prevalent CLBP cases, DDD comprised of nearly 12.8 million cases in the US in 2022, these cases are expected to further increase at a CAGR of approximately 0.8% throughout the forecast period (2023-2032).
• Among EU4 and the UK, the UK had the highest diagnosed prevalent population of DDD, with approximately 2.1 million cases, followed by Germany and France in 2022. On the other hand, Italy had the lowest prevalent population in the European region in 2022.
• In Japan, there were around 4.3 million diagnosed prevalent cases of DDD in 2019. These cases are expected to decrease at a significant CAGR due to decline in population.
• As per our analysis, in the 7MM, more females were diagnosed with DDD than males.
• As per DelveInsight's analysis, the diagnosed prevalent cases of DDD based on age were categorized into seven groups: 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and above.
• In 2022, within the 7MM, the highest number of cases for DDD belonged to the age group 50-59 years, totaling approximately 5.1 million.

Degenerative Disc Disease (DDD) Drug Chapters

The drug chapter segment of the DDD report encloses a detailed analysis of DDD marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands DDD clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs:

Rexlemestrocel-L (MPC-06-ID): Mesoblast, Ltd/Grunenthal

Mesoblast's rexlemestrocel-L, an investigational allogeneic human bone marrow-derived mesenchymal precursor cell (MPC) therapy. It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections, and have no further treatment option other than invasive and costly surgical interventions. The therapy has completed Phase III trial to evaluate the efficacy and safety of a single injection of rexlemestrocel-L alone or combined with hyaluronic acid (HA) in subjects with chronic low back pain.

IDCT (Rebonuputemcel): DiscGenics

IDCT (rebonuputemcel) is an investigational product that is under development by DiscGenics. IDCT is an allogeneic (donor-derived), non-invasive cell therapy. During treatment, a single dose of IDCT is injected into the painful disc percutaneously (non-surgically). DiscGenics has completed the Phase I/II trial of IDCT to evaluate the safety and tolerability of a single injection of IDCT in subjects with single-level, symptomatic early to moderate lumbar intervertebral disc degeneration.

Note: Detailed emerging therapies assessment will be provided in the final report of Degenerative Disc Disease (DDD).

Degenerative Disc Disease (DDD) Market Outlook

Degenerative Disc Disease has a diverse treatment classification associated with the disease landscape. The management of degenerative disc disease primarily revolves around the utilization of corticosteroids, NSAIDs, surgery, and others as needed.

NSAIDs, Opioids, and others are major revenue generators in the current treatment landscape.

The market for degenerative disc disease is expected to experience positive growth with the approval of potential drugs like Rexlemestrocel-L (MPC-06-ID), IDCT (Rebonuputemcel), and others.

• The Degenerative Disc Disease market's total size in the 7MM reached approximately USD 3,572 million in 2022. Projections indicate a substantial growth during the forecast period.
• Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 62%.
• In 2022, EU4 and the UK captured an estimated USD 900 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest market share in 2022, followed by the UK, France, and Spain. Italy accounted for the least market in the same year.
• Japan alone represented approximately 13% of the total DDD market in 2022, projected to increase at a substantial CAGR during the study period.
• The total market size of the DDD treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.

Degenerative Disc Disease (DDD) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, Rexlemestrocel-L (MPC-06-ID) in the US is expected to be launched by 2027.

Further detailed analysis of emerging therapies drug uptake in the report:

Degenerative Disc Disease (DDD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Degenerative Disc Disease (DDD) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on degenerative disc disease evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Columbia University Irving Medical Center, New York, United States; Department of Neurological Surgery, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York; Research Center for Occupational and Social Medicine Freiburg, BertoldstraBe 27, 79098 Freiburg, Germany; King's College Hospital London, the United Kingdom; Department of Orthopaedic Surgery, Wakayama Medical University, Wakayama, Japan, and others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or DDD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of degenerative disc disease, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the degenerative disc disease market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Degenerative Disc Disease (DDD) market.

Degenerative Disc Disease (DDD) Report Insights

• Patient Population
• Therapeutic Approaches
• Degenerative Disc Disease Pipeline Analysis
• Degenerative Disc Disease Market Size and Trends
• Existing and Future Market Opportunity

Degenerative Disc Disease (DDD) Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Degenerative Disc Disease Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Degenerative Disc Disease (DDD) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the degenerative disc disease total market size, the market size by therapies, and market share (%) distribution in 2019, and how would it all look in 2032? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of degenerative disc disease?
• What are the patents of emerging therapies for DDD?
• Which drug is going to be the largest contributor by 2032?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of degenerative disc disease? What will be the growth opportunities across the 7MM concerning the patient population of DDD?
• What is the historical and forecasted degenerative disc disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for DDD and why?
• What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating degenerative disc disease? What are the current guidelines for treating DDD in the US and Europe?
• How many companies are developing therapies for treating degenerative disc disease?
• How many emerging therapies are in the mid-stage and late stage of development for treating DDD?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for DDD?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted markets of degenerative disc disease?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Degenerative Disc Disease (DDD) Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The Degenerative Disc Disease (DDD) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2032, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the degenerative disc disease market?

The DDD market has several key players. The major players are Mesoblast, Ltd; Grunenthal; DiscGenics, and others which are currently developing drugs for the treatment of DDD.

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the degenerative disc disease market?

The increase in diagnosed prevalent cases of DDD and launch of emerging therapies are attributed to be the key drivers for increasing DDD market.

5. What is the expected impact of emerging therapies or advancements in degenerative disc disease treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the DDD treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the degenerative disc disease market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Degenerative Disc Disease (DDD) Market Overview at a Glance

• 3.1. Market Share (%) Distribution by Therapies of DDD in 2019
• 3.2. Market Share (%) Distribution by Therapies of DDD in 2032

4. Epidemiology and Market Methodology of DDD

5. Executive Summary of Degenerative Disc Disease (DDD)

6. Key Events

7. Degenerative Disc Disease (DDD) Background and Overview

• 7.1. Introduction
• 7.2. Types of DDD
• 7.3. Clinical Classification
• 7.4. Stages of DDD
• 7.5. Etiology
• 7.6. Risk Factors
• 7.7. Clinical Manifestations and Symptoms
• 7.8. Pathophysiology
• 7.9. Diagnosis
  • 7.9.1. Differential Diagnosis
• 7.10. Treatment and Management
  • 7.10.1. Treatment Algorithm

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale
  • 8.2.1. Diagnosed Prevalent Cases of Chronic Lower Back Pain
  • 8.2.2. Diagnosed Prevalent Cases of Disc Degeneration Disease
  • 8.2.3. Gender-specific Diagnosed Prevalent Cases of Disc Degeneration Disease
  • 8.2.4. Age-specific Diagnosed Prevalent Cases of Disc Degeneration Disease
• 8.3. Total Diagnosed Prevalent Cases of DDD in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of CLBP in the US
  • 8.4.2. Total Diagnosed Prevalent Cases of DDD in the US
  • 8.4.3. Gender-specific Diagnosed Prevalent Cases of DDD in the US
  • 8.4.4. Age-specific Diagnosed Prevalent Cases of DDD in the US
• 8.5. EU4 and the UK
  • 8.5.1. Germany
    • 8.5.1.1. Total Diagnosed Prevalent Cases of CLBP in Germany
    • 8.5.1.2. Total Diagnosed Prevalent Cases of DDD in Germany
    • 8.5.1.3. Gender-specific Diagnosed Prevalent Cases of DDD in Germany
    • 8.5.1.4. Age-specific Diagnosed Prevalent Cases of DDD in Germany
  • 8.5.2. France
    • 8.5.2.1. Total Diagnosed Prevalent Cases of CLBP in France
    • 8.5.2.2. Total Diagnosed Prevalent Cases of DDD in France
    • 8.5.2.3. Gender-specific Diagnosed Prevalent Cases of DDD in France
    • 8.5.2.4. Age-specific Diagnosed Prevalent Cases of DDD in France
  • 8.5.3. Italy
    • 8.5.3.1. Total Diagnosed Prevalent Cases of CLBP in Italy
    • 8.5.3.2. Total Diagnosed Prevalent Cases of DDD in Italy
    • 8.5.3.3. Gender-specific Diagnosed Prevalent Cases of DDD in Italy
    • 8.5.3.4. Age-specific Diagnosed Prevalent Cases of DDD in Italy
  • 8.5.4. Spain
    • 8.5.4.1. Total Diagnosed Prevalent Cases of CLBP in Spain
    • 8.5.4.2. Total Diagnosed Prevalent Cases of DDD in Spain
    • 8.5.4.3. Gender-specific Diagnosed Prevalent Cases of DDD in Spain
    • 8.5.4.4. Age-specific Diagnosed Prevalent Cases of DDD in Spain
  • 8.5.5. The United Kingdom
    • 8.5.5.1. Total Diagnosed Prevalent Cases of CLBP in the UK
    • 8.5.5.2. Total Diagnosed Prevalent Cases of DDD in the UK
    • 8.5.5.3. Gender-specific Diagnosed Prevalent Cases of DDD in the UK
    • 8.5.5.4. Age-specific Diagnosed Prevalent Cases of DDD in the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of CLBP in Japan
  • 8.6.2. Total Diagnosed Prevalent Cases of DDD in Japan
  • 8.6.3. Gender-specific Diagnosed Prevalent Cases of DDD in Japan
  • 8.6.4. Age-specific Diagnosed Prevalent Cases of DDD in Japan

9. Patient Journey

10. Emerging Therapies

• 10.1. Key Cross Competition of Emerging Drugs
• 10.2. Rexlemestrocel-L (MPC-06-ID): Mesoblast, Ltd. / Grunenthal
  • 10.2.1. Product Description
  • 10.2.2. Other Development Activities
  • 10.2.3. Clinical Development
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
  • 10.2.6. Product Profile
  • 10.2.7. Analysts' Views
• 10.3. IDCT (Rebonuputemcel): DiscGenics, Inc.
  • 10.3.1. Product Description
  • 10.3.2. Other Development Activities
  • 10.3.3. Clinical Development
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy
  • 10.3.6. Product Profile
  • 10.3.7. Analysts' Views
• 10.4. SB-01 (Peniel2000/P2K, YH14618): Spine Biopharma/Yuhan Corp
  • 10.4.1. Product Description
  • 10.4.2. Other Development Activities
  • 10.4.3. Clinical Development
  • 10.4.4. Clinical Trials Information
  • 10.4.5. Product Profile
  • 10.4.6. Analysts' Views
• 10.5. BRTX-100: BioRestorative Therapies
  • 10.5.1. Product Description
  • 10.5.2. Other Development Activities
  • 10.5.3. Clinical Development
  • 10.5.4. Clinical Trials Information
  • 10.5.5. Product Profile
  • 10.5.6. Analysts' Views
• 10.6. AMG0103 (NF-?B decoy oligonucleotide): AnGes, Inc./ Shionogi & Co., Ltd.
  • 10.6.1. Product Description
  • 10.6.2. Other Development Activities
  • 10.6.3. Clinical Development
  • 10.6.4. Clinical Trials Information
  • 10.6.5. Safety and Efficacy
  • 10.6.6. Product Profile
  • 10.6.7. Analysts' Views
• 10.7. KUR-113 (Fibrin-PTH): Kuros Biosurgery AG/Kuros Biosciences
  • 10.7.1. Product Description
  • 10.7.2. Other Development Activities
  • 10.7.3. Clinical Development
  • 10.7.4. Clinical Trials Information
  • 10.7.5. Product profile
  • 10.7.6. Analysts' Views
• 10.8. CELZ-201-DDT: Creative Medical Technology Holdings Inc.
  • 10.8.1. Product Description
  • 10.8.2. Other Development Activities
  • 10.8.3. Clinical Development
  • 10.8.4. Clinical Trials Information
  • 10.8.5. Product profile
  • 10.8.6. Analysts' Views
• 10.9. STA363: Stayble Therapeutics
  • 10.9.1. Product Description
  • 10.9.2. Other Development Activities
  • 10.9.3. Clinical Development
  • 10.9.4. Clinical Trials Information
  • 10.9.5. Safety and Efficacy
  • 10.9.6. Product Profile
  • 10.9.7. Analysts' Views
• 10.10. Allogenic BM-MSCs Injection: Citospin
  • 10.10.1. Product Description
  • 10.10.2. Clinical Development
  • 10.10.3. Clinical Trials Information
  • 10.10.4. Product profile
  • 10.10.5. Analysts' Views

11. DDD: Market Analysis

• 11.1. Key Findings
• 11.2. Key Market Forecast Assumptions
• 11.3. Market Outlook
• 11.4. Conjoint Analysis
• 11.5. Total Market Size of DDD in the 7MM
• 11.6. Market Size by Therapies of DDD in the 7MM
• 11.7. Market Size of DDD in the United States
  • 11.7.1. Total Market Size of DDD
  • 11.7.2. Market Size by Therapies of DDD
• 11.8. Market Size of DDD in EU4 and the UK
  • 11.8.1. Germany
    • 11.8.1.1. Total Market Size of DDD
    • 11.8.1.2. Market Size by Therapies of DDD
  • 11.8.2. France
    • 11.8.2.1. Total Market Size of DDD
    • 11.8.2.2. Market Size by Therapies of DDD
  • 11.8.3. Italy
    • 11.8.3.1. Total Market Size of DDD
    • 11.8.3.2. Market Size by Therapies of DDD
  • 11.8.4. Spain
    • 11.8.4.1. Total Market Size of DDD
    • 11.8.4.2. Market Size by Therapies of DDD
  • 11.8.5. The United Kingdom
    • 11.8.5.1. Total Market Size of DDD
    • 11.8.5.2. Market Size by Therapies of DDD
• 11.9. Market Size of DDD in Japan
  • 11.9.1. Total Market Size of DDD
  • 11.9.2. Market Size by Therapies of DDD

12. Key Opinion Leaders' Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

• 15.1. The United States
  • 15.1.1. Center for Medicare and Medicaid Services (CMS)
• 15.2. In EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. The United Kingdom
• 15.3. Japan
  • 15.3.1. MHLW

16. Appendix

• 16.1. Bibliography
• 16.2. Acronyms and Abbreviations
• 16.3. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

관련자료